Creative Biostructure to Present at AACR Annual Meeting 2024 | April 5-10, 2024 | Booth #2953 
COVID-19 Spike Protein (Omicron Variant)-mRNA Lipid Nanoparticle (LNP)(BSLNP-006Z)
| Product Summary | |
|---|---|
| Name | COVID-19 Spike Protein (Omicron Variant)-mRNA Lipid Nanoparticle (LNP) |
Download Datasheet
|
|
| Cat No. | BSLNP-006Z |
| Product Overview | This product encapsulates 50µg/mL COVID-19 Spike Protein (Alpha Variant)-mRNA in lipid nanoparticles. This product utilizes the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of the Omicron variant spike protein (COVID-19) mRNA to a variety of mammalian cells, including cell cultures which may typically be prone to difficulties in expressing desired proteins. |
| Form | Liquid |
| Storage Buffer | PBS |
| Storage | Store at 4°C |
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Frequently Asked Questions
-
Can you provide information on the size and composition of your liposomes?
Yes, we offer detailed specifications for each product, enabling researchers to select liposomes that best match their experimental requirements.
-
Do you offer customization options for liposome formulations?
Yes, we offer customization services to meet the unique demands of research projects. Our team of experts can work with customers to develop custom liposome formulations tailored to their specific needs, ensuring optimal results for their experiments.
-
What analytical and characterization data do you provide with your liposome products?
We provide comprehensive analytical and characterization data for all our liposome products, such as size distribution, zeta potential, and encapsulation efficiency.
